Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.46 |
| ▸ | TUBB | P07437 | 2/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8322730 | 0.82 | MEN1 (0.68) | MEN1KMT2AGAAKDM4EPOLB | |
| SCHEMBL9542251 | 0.82 | GAA (0.71) | MEN1KMT2AGAAKDM4EPOLB | |
| SCHEMBL2977343 | 0.81 | GAA (0.54) | MEN1KMT2AGAAKDM4EPOLB | |
| SCHEMBL207179 | 0.78 | GAA (0.62) | MEN1KMT2AGAAKDM4EPOLB | |
| Acetic Acid SCHEMBL8322644 | 0.78 | KMT2A (0.59) | MEN1KMT2AGAAKDM4EPOLB | |
| SCHEMBL2331661 | 0.77 | POLB (0.58) | MEN1KMT2AGAAKDM4EPOLB | |
| SCHEMBL4106588 | 0.77 | PTGS2 (0.55) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8533124 | 0.77 | GAA (0.60) | MEN1KMT2AGAAKDM4EPOLB | |
| SCHEMBL8026574 | 0.77 | GAA (0.60) | MEN1KMT2AGAAKDM4EPOLB | |
| SCHEMBL12473173 | 0.77 | PTGS2 (0.61) | MEN1KMT2AGAAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132817-A1 | Heterocyclic compounds, their production and use | NATSUGARI HIDEAKI (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1184036-A2 | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| EP-1145714-A1 | DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2001-10-17 | — | — | EP | disclosed |
| CN-1291099-A | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
| EP-1061926-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999047132-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132817-A1 | Heterocyclic compounds, their production and use | CRH, CRHR1, CRHR2 | MEN1 669/4885KMT2A 765/4885GAA 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.